All AbMole products are for research use only, cannot be used for human consumption.
Erdafitinib (JNJ-42756493) is a potent and selective orally bioavailable, pan FGFR inhibitor with potential antineoplastic activity. Erdafitinib (JNJ-42756493) inhibits FGFR1/2/3/4 with IC50s of 1.2, 2.5, 3.0 and 5.7 nM, respectively.
In vivo, Erdafitinib administration results in potent and dose-dependent antitumor activity accompanied by pharmacodynamic modulation of phospho-FGFR and phospho-ERK in tumors.
Int Immunopharmacol. 2024 Feb 15;128:111323.
Downregulation of S100A11 promotes T cell infiltration by regulating cancer-associated fibroblasts in prostate cancer
Erdafitinib purchased from AbMole
Mol Carcinog. 2024 Jan.
Knockout of Shcbp1 sensitizes immunotherapy by regulating α-SMA positive cancer-associated fibroblasts
Erdafitinib purchased from AbMole
| Molecular Weight | 446.54 |
| Formula | C25H30N6O2 |
| CAS Number | 1346242-81-6 |
| Solubility (25°C) | DMSO ≥ 40 mg/mL |
| Storage |
Powder -20°C 3 years ; 4°C 2 years In solvent -80°C 6 months ; -20°C 1 month |
| Related FGFR Products |
|---|
| SNIPER(TACC3)-11
SNIPER(TACC3)-11 is a potent FGFR3-TACC3 degrader. |
| LY-3076226
LY-3076226 is an antibody drug coupling (ADC) with a cleavable linker targeting FGFR2. |
| Aprutumab ixadotin
Aprutumab ixadotin is an antibody drug coupling (ADC) with a non-cleavable linker that targets FGFR2. |
| Gunagratinib
Gunagratinib is an orally active, potent, selective, and irreversible fibroblast growth factor receptor (pan-FGFR) inhibitor for use in cancer research. |
| SAR-442501
SAR-442501 is a novel anti-FGFR3 monoclonal antibody for studies related to achondroplasia (ACH). |
All AbMole products are for research use only, cannot be used for human consumption or veterinary use. We do not provide products or services to individuals. Please comply with the intended use and do not use AbMole products for any other purpose.
Products are for research use only. Not for human use. We do not sell to patients.
© Copyright 2010-2024 AbMole BioScience. All Rights Reserved.
